🌿 HEALTH + POLICY: The Future of Cannabis Reform Under Trump

In partnership with

In a surprising turn that could significantly impact public health policy and access to medical cannabis, former President Donald Trump has signaled openness to rescheduling marijuana—picking up where the Biden administration left off. While not full legalization, this potential move could reshape how cannabis is regulated and perceived in the U.S., particularly in the healthcare space.

The hidden costs of chronic pet conditions

Many pet owners don’t realize that chronic illnesses (like diabetes or allergies) can cost far more over a pet’s lifetime than a single emergency.

Pet insurance could save you thousands in repeat treatments and costs, so you’re not forced to choose between your pet’s health and other important expenses. Check out Money’s best pet insurance list to find plans starting at $10/month.

Find a plan

Trump mentioned this month that a decision on rescheduling marijuana may come within “the next few weeks,” raising both hope and skepticism within health advocacy circles.

🏥 A Health Shift, Not Just a Legal One

At the core of the rescheduling conversation is the proposed reclassification of marijuana from Schedule I—the strictest drug category with “no accepted medical use”—to Schedule III, which acknowledges medical applications and poses fewer regulatory hurdles.

While Biden’s administration initiated the process, it hit roadblocks within the DEA and never reached a conclusion. Experts like Adam Smith of the Marijuana Policy Project say the agency's longstanding resistance to cannabis reform played a key role in the delay.

If Trump follows through, the change could open doors for broader medical research, insurance coverage, and standardized safety regulations for cannabis products—especially important in a country where nearly 9 in 10 Americans support medical marijuana access.

💡 What This Could Mean for Public Health

From a health perspective, rescheduling marijuana could:

• Enable more clinical research into its effects on conditions like chronic pain, PTSD, and epilepsy.

• Reduce stigma around therapeutic cannabis use, making doctors more comfortable discussing it with patients.

• Improve safety standards by encouraging federal oversight of product quality and potency.

• Lower costs for patients if insurance companies begin covering medical marijuana therapies.

These shifts wouldn’t just benefit consumers—they could also support more robust health data and long-term studies on cannabis use, which are currently lacking due to federal restrictions.

⚖️ Still Not Legal—But a Step Toward Normalization

It’s important to note: rescheduling is not legalization. Federal penalties for possession or use would still technically exist, especially outside regulated systems. But a reclassification would remove some of the harshest legal and financial barriers that have hindered medical cannabis providers—and patients—from operating more freely.

Cannabis businesses, for example, would gain access to traditional tax deductions and financial services. Critics argue this is a windfall for the industry, but advocates counter that it’s a necessary correction to allow safe and legal access for millions of Americans who rely on cannabis for medical relief.

📈 Looking Ahead

Should Trump actively pursue this change, it could signal a broader shift in how both parties treat cannabis—not as a partisan wedge issue, but as a legitimate public health and regulatory matter.

With new leadership at the DEA and growing bipartisan support from voters, the future of cannabis reform may rest less on ideology and more on science, safety, and common sense.

Whether or not rescheduling moves forward this fall, one thing is clear: America’s relationship with marijuana is evolving—and healthcare may be at the center of that transformation.